BioCentury
ARTICLE | Clinical News

ViaDerm-Calcitonin: Phase I data

January 24, 2011 8:00 AM UTC

An open-label, crossover Phase I trial in 12 postmenopausal women showed that single doses of 60-300 µg ViaDerm-Calcitonin significantly reduced levels of the bone resorption and cartilage degradation...